EGFR and hematopoietic and lymphoid system neoplasm: First, we chose to exclude drugs used in the treatment of hematological neoplasms as they are outside our area of expertise; some drugs had to be excluded from the analysis due to different indications at the time of initial submission, such as gefitinib, whose first FDA approval was not contingent upon EGFR status, whereas approval from the EMA and ANVISA came years later, specifically for patients with EGFR mutations.